A detailed history of Alpha Centric Advisors LLC transactions in Sarepta Therapeutics, Inc. stock. As of the latest transaction made, Alpha Centric Advisors LLC holds 18,000 shares of SRPT stock, worth $1.92 Million. This represents 1.9% of its overall portfolio holdings.

Number of Shares
18,000
Previous 7,500 140.0%
Holding current value
$1.92 Million
Previous $1.19 Million 89.7%
% of portfolio
1.9%
Previous 0.98%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Oct 30, 2024

BUY
$124.33 - $156.75 $1.31 Million - $1.65 Million
10,500 Added 140.0%
18,000 $2.25 Million
Q2 2024

Jul 25, 2024

BUY
$113.33 - $163.85 $819,489 - $1.18 Million
7,231 Added 2688.1%
7,500 $1.19 Million
Q1 2024

Apr 24, 2024

SELL
$93.7 - $141.53 $3,373 - $5,095
-36 Reduced 11.8%
269 $34,000
Q4 2023

Feb 14, 2024

SELL
$67.31 - $124.76 $2,086 - $3,867
-31 Reduced 9.23%
305 $29,000
Q3 2023

Nov 13, 2023

SELL
$102.5 - $123.59 $5,842 - $7,044
-57 Reduced 14.5%
336 $40,000
Q2 2023

Aug 08, 2023

BUY
$106.4 - $157.19 $41,815 - $61,775
393 New
393 $45,000
Q3 2022

Nov 08, 2022

SELL
$75.71 - $119.24 $454,259 - $715,440
-6,000 Closed
0 $0
Q4 2021

Feb 25, 2022

SELL
$77.28 - $99.42 $231,840 - $298,260
-3,000 Reduced 33.33%
6,000 $540,000
Q3 2021

Mar 09, 2022

SELL
$65.97 - $92.48 $329,850 - $462,400
-5,000 Reduced 35.71%
9,000 $832,000
Q2 2021

Mar 09, 2022

BUY
$69.38 - $86.75 $312,210 - $390,375
4,500 Added 47.37%
14,000 $1.09 Million
Q1 2021

Mar 09, 2022

BUY
$72.25 - $168.95 $633,993 - $1.48 Million
8,775 Added 1210.34%
9,500 $708,000
Q4 2020

Mar 11, 2022

BUY
$125.56 - $178.74 $69,058 - $98,307
550 Added 314.29%
725 $124,000
Q3 2020

Mar 11, 2022

BUY
$127.12 - $172.34 $22,246 - $30,159
175 New
175 $25,000

Others Institutions Holding SRPT

About Sarepta Therapeutics, Inc.


  • Ticker SRPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 87,567,904
  • Market Cap $9.34B
  • Description
  • Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mut...
More about SRPT
Track This Portfolio

Track Alpha Centric Advisors LLC Portfolio

Follow Alpha Centric Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Alpha Centric Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Alpha Centric Advisors LLC with notifications on news.